Skip NavigationSkip to Content

X-linked carriers of chronic granulomatous disease: Illness, lyonization, and stability

  1. Author:
    Marciano, Beatriz E
    Zerbe, Christa S
    Falcone, E Liana
    Ding, Li
    DeRavin, Suk See
    Daub, Janine
    Kreuzburg, Samantha
    Yockey, Lynne
    Hunsberger, Sally
    Foruraghi, Ladan
    Barnhart, Lisa A
    Matharu, Kabir
    Anderson, Victoria
    Darnell, Dirk N
    Frein, Cathleen
    Fink, Dani
    Lau, Karen
    Long-Priel, Debra
    Gallin, John I
    Malech, Harry L
    Uzel, Gulbu
    Freeman, Alexandra F
    Kuhns, Doug
    Rosenzweig, Sergio D
    Holland, Steven M
  2. Author Address

    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH., Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, NIH., Biostatistics Branch, NIAID., Neutrophil Monitoring Lab, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Department of Laboratory Medicine, Clinical Center, NIH., Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH. Electronic address: smh@nih.gov.,
    1. Year: 2018
    2. Date: Jan
    3. Epub Date: 2017 May 17
  1. Journal: Journal of Allergy and Clinical Immunology
    1. 141
    2. 1
    3. Pages: 365-371
  2. Type of Article: Article
  1. Abstract:

    Chronic granulomatous disease (CGD) is characterized by recurrent life-threatening bacterial and fungal infections and aberrant inflammation. Mutations in CYBB cause X-linked CGD and account for 65%-70% of cases in western countries. To understand the clinical manifestations associated with the X-linked CGD carrier state. We undertook a comprehensive retrospective study of 162 affected females. We examined dihydrorhodamine oxidation (DHR) data for percent (%) X chromosome inactivation. We correlated lyonization (%DHR+) with clinical features. Where possible, we followed %DHR+ levels over time. Clinical data were available for 93 females: The %DHR+ was 46% (mean) and 47% (median)(SD=24). Using %DHR+ as the criterion for X inactivation, 78% of patients had levels of inactivation 20-80%, suggesting random inactivation that was independent of age. In contrast, carriers with CGD-type infections had median %DHR+ of 8% (n=14, range 0.06-48 %); those with only autoimmune or inflammatory manifestations (AIM) had median %DHR+ of 39% (n=31, range 7.4-74%). Those with both infections and autoimmunity had low %DHR+ (n=6, range=3-14%). A %DHR+ < 10 % was strongly associated with infections (OR:99). Strong association persisted when the %DHR+ was < 20% (OR=12) Autoimmunity was not associated with %DHR+. In two sets of identical twins the %DHR+ populations tracked closely over time. While the %DHR+ populations were very similar between sisters, those between mothers and daughters were unrelated. A low %DHR+ strongly predicts infection risk in X-linked CGD carriers, while the carrier state itself is associated with autoimmunity. Copyright © 2017. Published by Elsevier Inc.

    See More

External Sources

  1. DOI: 10.1016/j.jaci.2017.04.035
  2. PMID: 28528201
  3. WOS: 000419312200041

Library Notes

  1. Fiscal Year: FY2016-2017
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel